Pirinixic Acid NEW
Price | $41 | $58 | $72 |
Package | 10mg | 25mg | 50mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-19 |
Product Details
Product Name: Pirinixic Acid | CAS No.: 50892-23-4 |
Purity: 99.92% | Supply Ability: 10g |
Release date: 2024/11/19 |
Product Introduction
Bioactivity
Name | Pirinixic Acid |
Description | Pirinixic Acid (NSC 310038) is a synthetic thiacetic acid derivative used in biomedical research, carcinogenic Pirinixic acid is a peroxisome proliferator that activates specific peroxisome proliferator-activated receptors (PPAR). |
Kinase Assay | Fluorescence Polarization Assay: Binding of HSP90 inhibitors to human full-length recombinant HSP90β is determined by a competitive binding fluorescence polarization assay, using a fluorescent pyrazole resorcinol probe. |
In vitro | WY14643 significantly reduced visceral fat mass and total liver triglyceride content without increasing body weight. It enhanced systemic insulin sensitivity and improved insulin-mediated skeletal muscle glucose metabolism in both red (47%) and white (63%) muscle fibers, as well as in white adipose tissue (90%), while reducing muscle triglyceride and LCACoA accumulation. Administration of WY14643 (1 mg/kg i.v.) 30 minutes before left anterior descending artery occlusion led to a notable reduction in infarct size (~44%) in rats subjected to myocardial ischemia (25 minutes) followed by reperfusion (2 hours). In rats fed a high-fat diet, treatment with 3 mg/kg WY14643 lowered plasma glucose and triglyceride levels (-16% vs. untreated), leptin (-52%), muscle triglycerides (-34%), and overall long-chain acyl-coenzyme A (-41%) levels. |
In vivo | WY14643 (250 μM) significantly reduces the expression levels of VCAM-1, lowering it to 52% of those in human endothelial cells stimulated by TNF-α. At a concentration of 10 μM, WY 14643 acts on aortic smooth muscle cells to almost completely inhibit the production of IL-6 and prostaglandin induced by IL-1, as well as the expression of cyclooxygenase-2, through the suppression of the NF-κB signaling pathway. Pre-treating endothelial cells with WY 14643 (10 μM) before TNF-α stimulation decreases U937 cell adhesion by 50%. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 65 mg/mL (200.74 mM), Sonication is recommended. |
Keywords | Wy 14643 | Wy14643 | Pirinixic Acid | NSC310038 | Peroxisome proliferator-activated receptors | PPAR | inhibit | NSC-310038 | Inhibitor |
Inhibitors Related | Daidzein | Naringenin | 2,3-Butanediol |
Related Compound Libraries | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Endoplasmic Reticulum Stress Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Human Metabolite Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$180.00/1kg |
VIP1Y
|
Hebei Zhuanglai Chemical Trading Co.,Ltd
|
2024-04-30 | |
$0.00/25Kg/Drum |
VIP6Y
|
Jinan Finer Chemical Co., Ltd
|
2020-10-12 | |
$4.00/270Kg/Drum |
VIP5Y
|
Hebei Yanxi Chemical Co., Ltd.
|
2020-07-22 | |
$8.00/1KG |
VIP6Y
|
Career Henan Chemical Co
|
2020-02-17 |
- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hills
INQUIRY